El interés en corto de Dutch Bros da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Dutch Bros. Los datos de interés en corto se actualizan cada dos semanas.

Dutch Bros (NYSE:BROS) Bolsa, Informe de interés en corto

Dutch Bros

Dutch Bros Inc is an operator and franchisor of drive-thru coffee shops that are focused on serving hand-crafted beverages. The company's hand-crafted beverage-focused lineup features hot and cold espresso-based beverages, cold brew coffee products, proprietary energy drinks, tea, lemonade, smoothies and other beverages. The company has two reportable operating segments company-operated shops and franchising and other.

Dutch Bros Inc

<p>Argus Research  analyst Joseph Bonner   maintains Electronic Arts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>) with a Buy and raises the price target from $161 to $183.</p>


News

Price Target

Analyst Ratings

Argus Research Maintains Buy on Electronic Arts, Raises Price Target to $183

<p>Craig-Hallum  analyst Richard Shannon   maintains IonQ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>) with a Buy and raises the price target from $15 to $22.</p>


IONQ

Craig-Hallum Maintains Buy on IonQ, Raises Price Target to $22

<p><strong>Moleculin Biotech</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBRX#NASDAQ">MBRX</a>) is set to give its latest quarterly earnings report on Friday, 2024-11-08. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Moleculin Biotech will report an <strong>earnings per share</strong> (EPS) of $-2.44. </p>
<p>Investors in Moleculin Biotech are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Overview of Past Earnings</h3>
<p>In the previous earnings release, the company beat EPS by $0.61, leading to a 10.8% drop in the share price the following trading session.</p>
<p>Here's a look at Moleculin Biotech's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-2.31</td>
<td>-3.53</td>
<td>-3.05</td>
<td>-3.60</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-1.70</td>
<td>-2.02</td>
<td>-5.09</td>
<td>-2.85</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-11.0%</td>
<td>-0.0%</td>
<td>-14.000000000000002%</td>
<td>-5.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731006266_0.png" alt="eps graph" /></p>
<h3>Market Performance of Moleculin Biotech's Stock</h3>
<p>Shares of Moleculin Biotech were trading at $2.36 as of November 06. Over the last 52-week period, shares are down 71.6%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/MBRX/earnings"><strong>To track all earnings releases for Moleculin Biotech visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings

MBRX

Insights Ahead: Moleculin Biotech's Quarterly Earnings

<p>ANI Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIP#NASDAQ">ANIP</a>) is preparing to release its quarterly earnings on Friday, 2024-11-08. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect ANI Pharmaceuticals to report an <strong>earnings per share</strong> (EPS) of $1.07.</p>
<p>Anticipation surrounds ANI Pharmaceuticals's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Earnings History Snapshot</h3>
<p>Last quarter the company beat EPS by $0.08, which was followed by a 9.92% drop in the share price the next day.</p>
<p>Here's a look at ANI Pharmaceuticals's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.94</td>
<td>0.99</td>
<td>0.85</td>
<td>0.84</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.02</td>
<td>1.21</td>
<td>1</td>
<td>1.27</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-10.0%</td>
<td>3.0%</td>
<td>-1.0%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731006258_0.png" alt="eps graph" /></p>
<h3>ANI Pharmaceuticals Share Price Analysis</h3>
<p>Shares of ANI Pharmaceuticals were trading at $58.4 as of November 06. Over the last 52-week period, shares are up 12.64%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analyst Observations about ANI Pharmaceuticals</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on ANI Pharmaceuticals.</p>
<p>Analysts have given ANI Pharmaceuticals a total of 5 ratings, with the consensus rating being Neutral. The average one-year price target is $73.4, indicating a potential 25.68% upside.</p>
<h3>Comparing Ratings Among Industry Peers</h3>
<p>The following analysis focuses on the analyst ratings and average 1-year price targets of Tilray Brands, Collegium Pharmaceutical and Evolus, three prominent industry players, providing insights into their relative performance expectations and market positioning.</p>
<ul>
<li>For Tilray Brands, analysts project an Neutral trajectory, with an average 1-year price target of $1.75, indicating a potential 97.0% downside.</li>
<li>The consensus outlook from analysts is an Buy trajectory for Collegium Pharmaceutical, with an average 1-year price target of $41.5, indicating a potential 28.94% downside.</li>
<li>The consensus outlook from analysts is an Buy trajectory for Evolus, with an average 1-year price target of $24.6, indicating a potential 57.88% downside.</li>
</ul>
<h3>Snapshot: Peer Analysis</h3>
<p>Within the peer analysis summary, vital metrics for Tilray Brands, Collegium Pharmaceutical and Evolus are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANI Pharmaceuticals</td>
<td>Neutral</td>
<td>18.44%</td>
<td>$80.34M</td>
<td>-0.59%</td>
</tr>
<tr>
<td>Tilray Brands</td>
<td>Neutral</td>
<td>13.05%</td>
<td>$59.71M</td>
<td>-1.13%</td>
</tr>
<tr>
<td>Collegium Pharmaceutical</td>
<td>Buy</td>
<td>7.18%</td>
<td>$90.81M</td>
<td>8.94%</td>
</tr>
<tr>
<td>Evolus</td>
<td>Buy</td>
<td>35.59%</td>
<td>$47.83M</td>
<td>-60.12%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>ANI Pharmaceuticals ranks in the middle for consensus rating among its peers. It is at the bottom for revenue growth. In terms of gross profit, it is at the top among its peers. However, for return on equity, it is at the bottom compared to its peers.</p>
<h3>Discovering ANI Pharmaceuticals: A Closer Look</h3>
<p>ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.</p>
<h3>A Deep Dive into ANI Pharmaceuticals's Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> ANI Pharmaceuticals's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of <strong>18.44%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>-1.95%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> ANI Pharmaceuticals's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>-0.59%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> ANI Pharmaceuticals's ROA excels beyond industry benchmarks, reaching <strong>-0.29%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.63</strong>.</p>
<p><a href="https://www.benzinga.com/quote/ANIP/earnings"><strong>To track all earnings releases for ANI Pharmaceuticals visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


ANIP

A Peek at ANI Pharmaceuticals's Future Earnings

<p>InflaRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IFRX#NASDAQ">IFRX</a>) is gearing up to announce its quarterly earnings on Friday, 2024-11-08. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that InflaRx will report an <strong>earnings per share</strong> (EPS) of $-0.28.</p>
<p>InflaRx bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Earnings History Snapshot</h3>
<p>Last quarter the company missed EPS by $0.05, which was followed by a 2.99% increase in the share price the next day.</p>
<p>Here's a look at InflaRx's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.21</td>
<td>-0.24</td>
<td>-0.2</td>
<td>-0.25</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.26</td>
<td>-0.18</td>
<td>-0.3</td>
<td>-0.14</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>3.0%</td>
<td>0.0%</td>
<td>-3.0%</td>
<td>-14.000000000000002%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731006244_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of InflaRx were trading at $1.53 as of November 06. Over the last 52-week period, shares are up 17.97%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/IFRX/earnings"><strong>To track all earnings releases for InflaRx visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


IFRX

Earnings Preview: InflaRx

<p>Craig-Hallum  analyst Greg Palm   maintains Kornit Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRNT#NASDAQ">KRNT</a>) with a Buy and raises the price target from $27 to $33.</p>


KRNT

Craig-Hallum Maintains Buy on Kornit Digital, Raises Price Target to $33

<p><strong>Delcath Systems</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>) is set to give its latest quarterly earnings report on Friday, 2024-11-08. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Delcath Systems will report an <strong>earnings per share</strong> (EPS) of $-0.22. </p>
<p>The market awaits Delcath Systems's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Overview of Past Earnings</h3>
<p>During the last quarter, the company reported an EPS missed by $0.12, leading to a 4.93% drop in the share price on the subsequent day.</p>
<p>Here's a look at Delcath Systems's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.36</td>
<td>-0.47</td>
<td>-0.51</td>
<td>-0.52</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.48</td>
<td>-0.45</td>
<td>-0.48</td>
<td>-1.14</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-5.0%</td>
<td>2.0%</td>
<td>10.0%</td>
<td>-24.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731006227_0.png" alt="eps graph" /></p>
<h3>Market Performance of Delcath Systems's Stock</h3>
<p>Shares of Delcath Systems were trading at $10.94 as of November 06. Over the last 52-week period, shares are up 274.92%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analyst Insights on Delcath Systems</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Delcath Systems.</p>
<p>The consensus rating for Delcath Systems is Buy, derived from 2 analyst ratings. An average one-year price target of $21.5 implies a potential 96.53% upside.</p>
<h3>Comparing Ratings Among Industry Peers</h3>
<p>This comparison focuses on the analyst ratings and average 1-year price targets of Pulmonx, AngioDynamics and Zynex, three major players in the industry, shedding light on their relative performance expectations and market positioning.</p>
<ul>
<li>The consensus outlook from analysts is an Buy trajectory for Pulmonx, with an average 1-year price target of $16.0, indicating a potential 46.25% upside.</li>
<li>Analysts currently favor an Buy trajectory for AngioDynamics, with an average 1-year price target of $13.33, suggesting a potential 21.85% upside.</li>
<li>Zynex is maintaining an Buy status according to analysts, with an average 1-year price target of $14.67, indicating a potential 34.1% upside.</li>
</ul>
<h3>Peers Comparative Analysis Summary</h3>
<p>The peer analysis summary provides a snapshot of key metrics for Pulmonx, AngioDynamics and Zynex, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Delcath Systems</td>
<td>Buy</td>
<td>1468.89%</td>
<td>$6.25M</td>
<td>-146.09%</td>
</tr>
<tr>
<td>Pulmonx</td>
<td>Buy</td>
<td>15.39%</td>
<td>$15.03M</td>
<td>-14.50%</td>
</tr>
<tr>
<td>AngioDynamics</td>
<td>Buy</td>
<td>-14.22%</td>
<td>$36.72M</td>
<td>-6.36%</td>
</tr>
<tr>
<td>Zynex</td>
<td>Buy</td>
<td>0.10%</td>
<td>$39.79M</td>
<td>6.95%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Delcath Systems ranks first in revenue growth among its peers. It has the lowest gross profit margin. Delcath Systems has the lowest return on equity.</p>
<h3>Delving into Delcath Systems's Background</h3>
<p>Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.</p>
<h3>Breaking Down Delcath Systems's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Delcath Systems showcased positive performance, achieving a revenue growth rate of <strong>1468.89%</strong> as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> Delcath Systems's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>-176.94%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Delcath Systems's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>-146.09%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-39.25%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Delcath Systems's debt-to-equity ratio is below the industry average. With a ratio of <b>1.33</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<p><a href="https://www.benzinga.com/quote/DCTH/earnings"><strong>To track all earnings releases for Delcath Systems visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


DCTH

Uncovering Potential: Delcath Systems's Earnings Preview

<p>DA Davidson  analyst Wyatt Swanson   maintains Duolingo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOL#NASDAQ">DUOL</a>) with a Buy and raises the price target from $250 to $350.</p>


DUOL

DA Davidson Maintains Buy on Duolingo, Raises Price Target to $350

<p>Over the past 24 hours, <strong>Mantle's</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">MNT</a>) price has risen 14.54% to <strong>$0.68</strong>. This continues its positive trend over the past week where it has experienced a 12.0% gain, moving from $0.60 to its current price. As it stands right now, <strong>the coin's all-time high is $1.54</strong>. </p>
<p>The chart below compares the price movement and volatility for Mantle over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731006220_0.png" alt="price_chart" /></p>
<p>Mantle's trading volume has climbed 85.0% over the past week, moving in tandem, directionally, with the overall circulating supply of the coin, which has increased 0.35%. This brings the circulating supply to 3.37 billion, which makes up an estimated 54.14% of its max supply of 6.22 billion. According to our data, the current market cap ranking for MNT is #48 at $2.28 billion.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731006221_1.png" alt="supply_and_vol" /></p>
<p><a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

Movers

Trading Ideas

$MNT

Cryptocurrency Mantle's Price Increased More Than 14% Within 24 hours

<p>CompoSecure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPO#NASDAQ">CMPO</a>) is preparing to release its quarterly earnings on Friday, 2024-11-08. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect CompoSecure to report an <strong>earnings per share</strong> (EPS) of $0.29.</p>
<p>CompoSecure bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Overview of Past Earnings</h3>
<p>Last quarter the company beat EPS by $0.02, which was followed by a 29.16% increase in the share price the next day.</p>
<p>Here's a look at CompoSecure's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.25</td>
<td>0.25</td>
<td>0.23</td>
<td>0.25</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.27</td>
<td>0.25</td>
<td>0.26</td>
<td>0.24</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>28.999999999999996%</td>
<td>4.0%</td>
<td>26.0%</td>
<td>-9.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731006214_0.png" alt="eps graph" /></p>
<h3>Tracking CompoSecure's Stock Performance</h3>
<p>Shares of CompoSecure were trading at $15.48 as of November 06. Over the last 52-week period, shares are up 207.39%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/CMPO/earnings"><strong>To track all earnings releases for CompoSecure visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


CMPO

A Look at CompoSecure's Upcoming Earnings Report

<p>Holley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLLY#NYSE">HLLY</a>) is preparing to release its quarterly earnings on Friday, 2024-11-08. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Holley to report an <strong>earnings per share</strong> (EPS) of $0.03.</p>
<p>Investors in Holley are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Past Earnings Performance</h3>
<p>In the previous earnings release, the company missed EPS by $0.00, leading to a 1.88% drop in the share price the following trading session.</p>
<p>Here's a look at Holley's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.1</td>
<td>0.05</td>
<td>0.02</td>
<td>0.03</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.1</td>
<td>0</td>
<td>0</td>
<td>0.03</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-2.0%</td>
<td>-1.0%</td>
<td>-0.0%</td>
<td>-7.000000000000001%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731006187_0_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Holley were trading at $2.84 as of November 06. Over the last 52-week period, shares are down 27.08%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. </p>
<h3>Analysts' Take on Holley</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Holley.</p>
<p>With 3 analyst ratings, Holley has a consensus rating of Buy. The average one-year price target is $9.83, indicating a potential 246.13% upside.</p>
<h3>Analyzing Ratings Among Peers</h3>
<p>The analysis below examines the analyst ratings and average 1-year price targets of Stoneridge and Solid Power, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.</p>
<ul>
<li>The prevailing sentiment among analysts is an Outperform trajectory for Stoneridge, with an average 1-year price target of $16.0, implying a potential 463.38% upside.</li>
<li>For Solid Power, analysts project an Underperform trajectory, with an average 1-year price target of $1.0, indicating a potential 64.79% downside.</li>
</ul>
<h3>Snapshot: Peer Analysis</h3>
<p>The peer analysis summary presents essential metrics for Stoneridge and Solid Power, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Holley</td>
<td>Buy</td>
<td>-3.29%</td>
<td>$70.29M</td>
<td>3.77%</td>
</tr>
<tr>
<td>Stoneridge</td>
<td>Outperform</td>
<td>-10.22%</td>
<td>$44.49M</td>
<td>-2.61%</td>
</tr>
<tr>
<td>Solid Power</td>
<td>Underperform</td>
<td>3.44%</td>
<td>$-362K</td>
<td>-4.76%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Holley is positioned at the top for Revenue Growth among its peers. It ranks in the middle for Gross Profit. Holley is at the top for Return on Equity.</p>
<h3>Unveiling the Story Behind Holley</h3>
<p>Holley Inc is a designer, marketer, and manufacturer of high-performance automotive aftermarket products, featuring a portfolio of iconic brands serving the car and truck industry. It offers a diversified line of performance automotive products including fuel injection systems, tuners, exhaust products, carburetors, safety equipment and various other performance automotive products. The Company's products are designed to enhance street, off-road, recreational and competitive vehicle performance through increased horsepower, torque and drivability. The company's brands include Holley, APR, MSD and Flowmaster, among others. It derives revenue from the U.S. and Italy, of which prime revenue is derived from the U.S.</p>
<h3>Holley: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, Holley faced challenges, resulting in a decline of approximately <strong>-3.29%</strong> in revenue growth as of 30 June, 2024. This signifies a reduction in the company's top-line earnings. When compared to others in the Consumer Discretionary sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Holley's net margin is impressive, surpassing industry averages. With a net margin of <strong>10.09%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Holley's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>3.77%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Holley's ROA excels beyond industry benchmarks, reaching <strong>1.43%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>1.21</strong>, caution is advised due to increased financial risk.</p>
<p><a href="https://www.benzinga.com/quote/HLLY/earnings"><strong>To track all earnings releases for Holley visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


HLLY

What's Next: Holley's Earnings Preview

<p>U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 200 points on Thursday.</p>
<p>The Dow traded up 0.03% to 43,743.75 while the NASDAQ rose 1.30% to 19,231.18. The S&amp;P 500 also rose, gaining, 0.63% to 5,966.19.</p>
<p>Check This Out: <a href="https://www.benzinga.com/news/24/11/41801967/top-3-energy-stocks-that-are-ticking-portfolio-bombs">Top 3 Energy Stocks That Are Ticking Portfolio Bombs</a></p>
<p><strong>Leading and Lagging Sectors</strong><br /><br />Communication services shares surged by 1.7% on Thursday.</p>
<p>In trading on Thursday, financials shares fell by 1.4%.</p>
<p><strong>Top Headline</strong></p>
<p>U.S. initial jobless claims rose by 3,000 from the previous week to 221,000 in the final week of October, in-line with market expectations.</p>
<p><strong>Equities Trading UP</strong><br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
<ul>
<li><strong>AppLovin Corporation </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) shares shot up 43% to $241.00 after the company reported better-than-expected quarterly financial results.</li>
<li>Shares of <strong>Emergent BioSolutions Inc. </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) got a boost, surging 26% to $11.58 after the company announced it evaluated the safety and efficacy of its new clinical trial of Brincidofovir in treating Mpox across Africa. PANTHER will conduct a clinical trial under The Leadership of Africa Centres for Disease Control and Prevention.</li>
<li><strong>Dutch Bros Inc. </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BROS#NYSE">BROS</a>) shares were also up, gaining 34% to $46.72 following third-quarter earnings.</li>
</ul>
<p><strong>Equities Trading DOWN</strong></p>
<ul>
<li><strong>DENTSPLY SIRONA Inc. </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) shares dropped 26% to $17.65 after the company lowered its FY24 guidance and Leerink Partners downgraded the stock from Outperform to Market Perform.</li>
<li>Shares of <strong>Digital Turbine, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APPS#NASDAQ">APPS</a>) were down 49% to $1.66 after the company reported worse-than-expected second-quarter financial results.</li>
<li><strong>CommScope Holding Company, Inc. </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COMM#NASDAQ">COMM</a>) was down, falling 23% to $5.32 after the company reported worse-than-expected third-quarter financial results.</li>
</ul>
<p><strong>Commodities</strong><br /><br />In commodity news, oil traded up 1.3% to $72.63 while gold traded up 1.1% at $2,705.70.</p>
<p>Silver traded up 1.8% to $31.89 on Thursday, while copper rose 4.3% to $4.4270.</p>
<p><strong>Euro zone</strong></p>
<p>European shares closed mostly higher today. The eurozone's STOXX 600 gained 0.62%, Germany's DAX gained 1.70% and France's CAC 40 rose 0.76%. Spain's IBEX 35 Index rose 0.65%, while London's FTSE 100 fell 0.32%.</p>
<p>The Bank of England cut its Bank Rate by 25bps to 4.75% at its recent meeting. Retail sales in the Eurozone rose 0.5% month-over-month in September versus a revised 1.1% gain in August. The HCOB Eurozone construction PMI climbed to 43.0 in October from 42.1 in the previous month.</p>
<p>The S&amp;P Global France construction PMI climbed to 42.2 in October from 37.9 in the prior month, while German construction PMI declined to 40.2 in October from 41.7 in the previous month.</p>
<p><strong>Asia Pacific Markets</strong></p>
<p>Asian markets closed mixed on Thursday, with Japan's Nikkei 225 falling 0.25%, Hong Kong's Hang Seng Index gaining 2.02%, China's Shanghai Composite Index gaining 2.57% and India's BSE Sensex falling 1.04%.</p>
<p>China&#8217;s trade surplus widened to $95.27 billion in October from $56.13 billion in the year-ago period. Foreign exchange reserves in Singapore increased to SGD 507.6 billion in October from SGD 499.7 billion in the prior month.</p>
<p><strong>Economics</strong></p>
<ul>
<li>U.S. initial jobless claims rose by 3,000 from the previous week to 221,000 in the final week of October, in-line with market expectations.</li>
<li>U.S. nonfarm business sector labor productivity increased by 2.2% in the third quarter compared to a revised 2.1% gain in the prior three-month period.</li>
<li>Unit labor costs in the nonfarm business sector rose an annualized 1.9% during the third quarter compared to a revised 2.4% increase in the earlier period.</li>
<li>U.S. wholesale inventories fell by 0.2% month-over-month to $903.7 billion in September versus the preliminary reading of a 0.1% decline and compared to a 0.2% gain in the prior month.</li>
<li>U.S. natural-gas stocks rose by 69 billion cubic feet to 3.932 trillion cubic feet in the week ended Nov. 1.</li>
</ul>
<p><strong>Now Read This: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/news/24/11/41805406/wall-streets-most-accurate-analysts-spotlight-on-3-industrials-stocks-with-over-5-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Industrials Stocks With Over 5% Dividend Yields</a></strong></li>
</ul>


Equities

Eurozone

Commodities

Intraday Update

APPS

BROS

COMM

XRAY

Crude Oil Rises 1%; US Jobless Claims Increase To 221,000

<p>The Russell 2000 Index, which tracks US small-cap companies, rose about 6% to near-record highs and recorded the largest single-day gain in two years. The astounding surge came in the wake of Donald Trump&#39;s victory in the presidential election.<br />
Analysts expect Trump&#39;s victory to lead to faster economic growth and more market-friendly policies. This is because Trump supports lower corporate tax rates, deregulation and other policies that favor domestic growth, all of which would provide more stimulus to the U.S. economy and benefit riskier assets. The anticipation of greater tariff barriers and a step to move manufacturing back home will drive small-cap stocks higher (read: <a href="https://www.zacks.com/stock/news/2365355/etfs-set-to-soar-on-trumps-presidential-victory" target="_blank">ETFs Set to Soar on Trump&#39;s Presidential Victory</a>).<br />
In order to tap this trend, investors should consider small-cap ETFs for diversified exposure across several sectors. We have highlighted five funds that have a Zacks ETF Rank #2 (Buy) each, suggesting their outperformance in the coming weeks. These are <strong>iShares Core S&amp;P Small-Cap ETF</strong> IJR, <strong>iShares Russell 2000 ETF</strong> IWM, <strong>Vanguard Small-Cap ETF</strong> VB, <strong>Schwab U.S. Small-Cap ETF</strong> SCHA and <strong>SPDR Portfolio S&amp;P 600 Small Cap ETF</strong> SPSM.</p>
<h3>Corporate Tax Cuts</h3>
<p>Trump recently proposed reducing the statutory corporate income tax rate from 21% to 15%. He also promised to extend tax cuts passed during his first term &mdash; set to expire at the end of next year. With reduced tax expenses, profits for smaller companies will grow.</p>
<h3>Deregulation</h3>
<p>Trump&#39;s administration is focused on deregulating many industries like energy and finance aiming to reduce the compliance costs, which businesses face. For small-cap companies, which often lack the financial resources of larger firms to manage regulatory compliance, reduced regulations mean lower operational costs. This shift will allow small-cap businesses to operate with increased profitability.</p>
<h2>Protectionist Stance</h2>
<p>Trump&#39;s proposed tariffs against major U.S. trading partners would boost the greenback. A strong dollar provides an edge to domestic-focused companies as small caps do not have much exposure to the international market. As such, Trump&#39;s protectionist stance will benefit domestic producers, as higher import tariffs raise costs for foreign competitors.</p>
<h3>More Rate Cuts In The Cards</h3>
<p>After initiating a 50-bps rate cut in September, the Fed is expected to cut interest rates further this year. As the pint-sized companies have a higher debt burden (mostly at floating rates), lower rates lead to reduced borrowing costs, helping small businesses expand their operations easily and resulting in increased profitability. This, in turn, stimulates economic growth. As small-cap companies are more domestically tied, these are poised to outperform when the economy improves.</p>
<h3>Geopolitics</h3>
<p>Small-cap stocks are considered safer and better plays if political issues or economic turmoil creep into the picture. Escalating tensions in the Middle East and the ongoing Russia-Ukraine war are driving the appeal for small-cap stocks.</p>
<h3>ETFs Set To Explode</h3>
<p><strong>iShares Core S&amp;P Small-Cap ETF (ARCA:IJR)&nbsp;</strong><br />
iShares Core S&amp;P Small-Cap ETF offers exposure to U.S. small-cap stocks and follows the S&amp;P SmallCap 600 Index. iShares Core S&amp;P Small-Cap ETF holds 662 stocks in its basket, with none accounting for more than 0.8% of the assets. Financials, industrials, consumer discretionary and information technology are the top four sectors with double-digit exposure each.&nbsp;<br />
iShares Core S&amp;P Small-Cap ETF is the largest and most popular ETF in the small-cap space, with AUM of $85.3 billion and an average daily volume of 3 million shares. The product charges investors 6 bps in annual fees.<br />
<strong>iShares Russell 2000 ETF (ARCA:IWM)</strong><br />
iShares Russell 2000 ETF is the largest and most popular ETF in the small-cap space, with an AUM of $68.9 billion and an average daily volume of 33 million shares. It tracks the Russell 2000 Index and holds well-diversified 1,973 stocks in its basket. IWM has key holdings in financials, healthcare, industrials and information technology.<br />
iShares Russell 2000 ETF charges 19 bps in annual fees (read: <a href="https://www.zacks.com/stock/news/2364988/etf-strategies-to-consider-as-trump-nears-victory?art_rec=etfs-overview-zacks_news-ID05-txt-2364988" target="_blank">ETF Strategies to Consider as Trump Nears Victory</a>).<br />
<strong>Vanguard Small-Cap ETF (ARCA:VB)&nbsp;</strong><br />
Vanguard Small-Cap ETF follows the CRSP US Small Cap Index and holds a basket of 1,384 stocks, with none holding more than 0.5% of the assets. Vanguard Small-Cap ETF is widely spread across various sectors, with industrials, consumer discretionary, financials, information technology and healthcare being the top five.<br />
Vanguard Small-Cap ETF has AUM of $60.5 billion and trades in a solid average daily volume of about 549,000 shares. VB charges 5 bps in fees per year from investors.&nbsp;<br />
<strong>Schwab U.S. Small-Cap ETF (ARCA:SCHA)</strong><br />
Schwab U.S. Small-Cap ETF tracks the Dow Jones U.S. Small-Cap Total Stock Market Index, holding 1,745 stocks in its basket. Each security accounts for less than 0.3% of the assets. Schwab U.S. Small-Cap ETF is widely spread across sectors, with financials, industrials, health care, information technology and consumer discretionary having double-digit exposure each.<br />
Schwab U.S. Small-Cap ETF has AUM of $18 billion and sees a solid volume of around 1 million shares a day. It has an expense ratio of 0.04%.&nbsp;<br />
<strong>SPDR Portfolio S&amp;P 600 Small Cap ETF (ARCA:SPSM)</strong><br />
SPDR Portfolio S&amp;P 600 Small Cap ETF follows the S&amp;P Small Cap 600 Index, holding 605 stocks in its basket. None of the firms make up more than 0.7% of the assets. SPDR Portfolio S&amp;P 600 Small Cap ETF is also widely spread out across sectors, with financials, industrials, consumer discretionary, information technology and healthcare having double-digit exposure each.&nbsp;<br />
SPDR Portfolio S&amp;P 600 Small Cap ETF has been able to manage $11.9 billion in its asset base and trades in a good volume of 1.3 million shares a day on average. SPSM charges 3 bps in annual fees.</p>
<p><a href="https://www.zacks.com/stock/news/2366589/small-cap-etfs-set-to-explode-under-trump-presidency?cid=CS-BENZ-FT-etf_news_and_commentary-2366589">To read this article on Zacks.com click here.</a></p>


ETFs

Small-Cap ETFs Set To Explode Under Trump Presidency

<p>Over the past 24 hours, <strong>OKB's</strong> (CRYPTO:OKB) price has risen 3.06% to <strong>$40.34</strong>. This continues its positive trend over the past week where it has experienced a 5.0% gain, moving from $38.23 to its current price. As it stands right now, <strong>the coin's all-time high is $73.80</strong>. </p>
<p>The chart below compares the price movement and volatility for OKB over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731006154_0.png" alt="price_chart" /></p>
<p><strong>The trading volume for the coin has increased 170.0%</strong> over the past week while the overall circulating supply of the coin has increased 0.39% to over 60.00 million which makes up an estimated 20.0% of its max supply, which is 300.00 million. The current market cap ranking for <strong>OKB</strong> is <strong>#44</strong> at <strong>$2.42 billion</strong>.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731006154_1.png" alt="supply_and_vol" /></p>
<p><a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Cryptocurrency OKB's Price Increased More Than 3% Within 24 hours

<p>Y-mAbs Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) is preparing to release its quarterly earnings on Friday, 2024-11-08. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Y-mAbs Therapeutics to report an <strong>earnings per share</strong> (EPS) of $-0.15.</p>
<p>Investors in Y-mAbs Therapeutics are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Overview of Past Earnings</h3>
<p>The company's EPS missed by $0.08 in the last quarter, leading to a 8.74% increase in the share price on the following day.</p>
<p>Here's a look at Y-mAbs Therapeutics's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.13</td>
<td>-0.14</td>
<td>-0.20</td>
<td>-0.19</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.21</td>
<td>-0.15</td>
<td>-0.02</td>
<td>-0.18</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>9.0%</td>
<td>-21.0%</td>
<td>12.0%</td>
<td>10.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731006153_0.png" alt="eps graph" /></p>
<h3>Performance of Y-mAbs Therapeutics Shares</h3>
<p>Shares of Y-mAbs Therapeutics were trading at $15.69 as of November 06. Over the last 52-week period, shares are up 215.45%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. </p>
<h3>Analyst Insights on Y-mAbs Therapeutics</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Y-mAbs Therapeutics.</p>
<p>The consensus rating for Y-mAbs Therapeutics is Outperform, derived from 7 analyst ratings. An average one-year price target of $21.0 implies a potential 33.84% upside.</p>
<h3>Analyzing Analyst Ratings Among Peers</h3>
<p>In this analysis, we delve into the analyst ratings and average 1-year price targets of  and Avid Bioservices, three key industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Avid Bioservices is maintaining an Outperform status according to analysts, with an average 1-year price target of $12.17, indicating a potential 22.43% downside.</li>
</ul>
<h3>Peer Metrics Summary</h3>
<p>The peer analysis summary presents essential metrics for  and Avid Bioservices, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Y-mAbs Therapeutics</td>
<td>Outperform</td>
<td>9.86%</td>
<td>$19.78M</td>
<td>-9.51%</td>
</tr>
<tr>
<td>Avid Bioservices</td>
<td>Outperform</td>
<td>6.49%</td>
<td>$5.71M</td>
<td>-9.26%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Y-mAbs Therapeutics ranks higher than its peers in terms of Revenue Growth and Gross Profit, indicating stronger financial performance in these areas. However, it lags behind in terms of Return on Equity. Overall, Y-mAbs Therapeutics is positioned towards the top compared to its peers based on the provided metrics.</p>
<h3>Delving into Y-mAbs Therapeutics's Background</h3>
<p>Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.</p>
<h3>Financial Milestones: Y-mAbs Therapeutics's Journey</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Y-mAbs Therapeutics's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of <strong>9.86%</strong>. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Y-mAbs Therapeutics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>-40.57%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>-9.51%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Y-mAbs Therapeutics's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>-6.92%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.01</strong>, Y-mAbs Therapeutics adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<p><a href="https://www.benzinga.com/quote/YMAB/earnings"><strong>To track all earnings releases for Y-mAbs Therapeutics visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


YMAB

Examining the Future: Y-mAbs Therapeutics's Earnings Outlook

<p>Over the past 24 hours, <strong>Cronos's</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">CRO</a>) price has risen 9.17% to <strong>$0.09</strong>. This continues its positive trend over the past week where it has experienced a 25.0% gain, moving from $0.07 to its current price. As it stands right now, <strong>the coin's all-time high is $0.97</strong>. </p>
<p>The chart below compares the price movement and volatility for Cronos over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731006145_0.png" alt="price_chart" /></p>
<p>The trading volume for the coin has climbed 366.0% over the past week, moving opposite, directionally, with the overall circulating supply of the coin, which has decreased 0.71%. This brings the circulating supply to 27.09 billion. According to our data, the current market cap ranking for CRO is #43 at $2.50 billion.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731006145_1.png" alt="supply_and_vol" /></p>
<p><a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


$CRO

Cryptocurrency Cronos's Price Increased More Than 9% Within 24 hours

Federal Reserve

Fed Says Labor Market Conditions Have 'Generally Eased,' Unemployment Rate Has Moved Up But Remains Low; Economic Activity Has Continued To Expand At A Solid Pace; Says Will Continue Reducing Bond Holdings At Previously Announced Pace; Vote In Favor Of Policy Was Unanimous

<p>Craig-Hallum  analyst Jason Kreyer   maintains Zillow Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZG#NASDAQ">ZG</a>) with a Buy and raises the price target from $55 to $70.</p>


Craig-Hallum Maintains Buy on Zillow Gr, Raises Price Target to $70

<p>Compass Point  analyst Floris Van Dijkum   maintains Macerich (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAC#NYSE">MAC</a>) with a Buy and raises the price target from $20 to $23.</p>


Compass Point Maintains Buy on Macerich, Raises Price Target to $23

<p>During the last three months, 4 analysts shared their evaluations of Beacon Roofing Supply (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BECN#NASDAQ">BECN</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $123.25, a high estimate of $140.00, and a low estimate of $114.00. Observing a 3.14% increase, the current average has risen from the previous average price target of $119.50. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731006100_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>The standing of Beacon Roofing Supply among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Rehaut</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$119.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Mike Dahl</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$114.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Reuben Garner</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$140.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>David Manthey</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$120.00</td>
<td>$115.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Beacon Roofing Supply. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Beacon Roofing Supply compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Beacon Roofing Supply's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Beacon Roofing Supply's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/BECN/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Beacon Roofing Supply analyst ratings.</strong></a></p>
<h2>Get to Know Beacon Roofing Supply Better</h2>
<p>Beacon Roofing Supply Inc manufactures and sells roofing and building materials throughout the United States and Canada. Beacon's key customers consist of contractors, home builders, lumberyards, retailers, wholesale distributors, and building materials suppliers. The company's product portfolio includes both residential and non-residential roofing materials, siding, windows, and waterproofing systems. The majority of revenue is generated from residential and non-residential roofing products. The vast majority of Beacon's revenue comes from the United States.</p>
<h3>Key Indicators: Beacon Roofing Supply's Financial Health</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Beacon Roofing Supply showcased positive performance, achieving a revenue growth rate of <strong>7.29%</strong> as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Industrials sector.</p>
<p><strong>Net Margin:</strong> Beacon Roofing Supply's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>5.24%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>7.96%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Beacon Roofing Supply's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>1.97%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>1.95</strong>, Beacon Roofing Supply adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


BECN

Forecasting The Future: 4 Analyst Projections For Beacon Roofing Supply

Andrew Charles, an analyst from TD Cowen, maintained the Buy rating on Dutch Bros Inc (BROS – Research Report). The associated price target is $53....

Strong Buy Rating for Dutch Bros Inc. Amid Impressive Q3 Performance and Expansion Plans

Barclays analyst Jeff Bernstein maintained a Hold rating on Dutch Bros Inc (BROS – Research Report) today and set a price target of $31.00. The com...

Barclays Sticks to Their Hold Rating for Dutch Bros Inc (BROS)

Bank of America Securities analyst Sara Senatore has reiterated their bullish stance on BROS stock, giving a Buy rating yesterday. Sara Senatore's ...

Dutch Bros Inc's Strong Q3 Performance and Growth Outlook Reaffirm 'Buy' Rating

BofA raised the firm's price target on Dutch Bros (BROS) to $51 from $49 and keeps a Buy rating on the shares. The company's Q3 same-store sales gr...

Dutch Bros price target raised to $51 from $49 at BofA

Nick Setyan, an analyst from Wedbush, maintained the Buy rating on Dutch Bros Inc (BROS – Research Report). The associated price target was raised ...

Optimistic Outlook for Dutch Bros: Buy Rating Backed by Strong SSS Growth, Raised Guidance, and Promising Future Prospects

Dutch Bros (BROS) is up 36.8%, or $12.87 to $47.80. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial...

Dutch Bros rises 36.8%

Dutch Bros (BROS) is up 31.7%, or $11.07 to $46.01. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial...

Dutch Bros rises 31.7%

Dutch Bros pops 40% after highlighting that it may be a bigger player in the food game

Get caught up quickly on the top news and calls moving stocks with these

Qualcomm, Moderna report quarterly beats: Morning Buzz

Dutch Bros (BROS) is up 37.5%, or $13.10 to $48.04. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial...

Dutch Bros rises 37.5%

DLTR

FIVE

FRSH

GOEV

MRNA

NSANF

NSANY

PLTR

QCOM

SBUX

SEDG

SRPT

TTWO

USFD

WOLF

Press Releases

Leading Restaurant Executive Joins Dutch Bros Board of Directors

Dutch Bros Inc. Announces Launch of Secondary Public Offering of Class A Common Stock

Former Wendy's CEO Joins Dutch Bros Board of Directors

Dutch Bros Keeps Cool with New Chillin' with Dutch Drinks

Dutch Bros Inc. to Host Second Quarter 2024 Conference Call and Webcast on August 7, 2024

Dutch Bros Inc. Reports Second Quarter 2024 Financial Results

Fall in Luv with Dutch Bros' New Drinks

Dutch Bros Inc. to Host Third Quarter 2024 Conference Call and Webcast on November 6, 2024

Sleigh the Season: Dutch Bros Unwraps 2024 Holiday Menu

Dutch Bros Inc. Reports Third Quarter 2024 Financial Results

BALL

PRGO

PTLO

RRGB

TXRH

Arcos Dorados Holdings Inc. Class A Shares

Arcos Dorados Holdings

Aramark

Bloomin Brands

The Cheesecake Factory Incorporated - Common Stock

Cheesecake Factory

Cava Group

Cracker Barrel Old Country Store, Inc. - Common Stock

Cracker Barrel Old

Chipotle Mexican Grill, Inc. Common Stock

Chipotle Mexican Grill

DoorDash

Krispy Kreme

Domino's Pizza

Darden Restaurants

Brinker International

First Watch Restaurant Group, Inc. - Common Stock

First Watch Restaurant Gr

SUPER HI INTERNATIONAL HOLDING LTD. - American Depositary Shares

Super Hi International

Kura Sushi USA, Inc. - Class A Common Stock

Kura Sushi USA

McDonald's

Papa John's International, Inc. - Common Stock

Papa John's International

Starbucks

Sweetgreen

Shake Shack

Texas Roadhouse

Wendy's

Wingstop

Yum Brands

Yum China Holdings

JP Morgan

Baird

Wedbush

TD Cowen

WIIM

Dutch Bros shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY24 revenue guidance above estimates.

Comments

Dutch Bros

Interés en corto

Dutch Bros (NYSE:BROS) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL